Patricia Gilleaudeau

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

Lisa C. Zaba, Irma Cardinale, Patricia Gilleaudeau et al. · The Journal of Experimental Medicine · 2007 · 668 citations · Full text

Medicine, Dermatology, Immunology +13

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

Scott Gottlieb, Patricia Gilleaudeau, Ray A. Johnson et al. · Nature Medicine · 1995 · 614 citations

Medicine, Dermatology, Immunology +16

Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

Michelle A. Lowes, Francesca Chamian, Maria Veronica Abello et al. · Proceedings of the National Academy of Sciences · 2005 · 450 citations · Full text

Medicine, Dermatology, Immunology +17

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Emma Guttman‐Yassky, Patrick M. Brunner, Avidan U. Neumann et al. · Journal of the American Academy of Dermatology · 2018 · 338 citations · Full text

Medicine, Dermatology, Immunology +14

Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells.

James G. Krueger, Jonathan Wolfe, R Nabeya et al. · The Journal of Experimental Medicine · 1995 · 249 citations · Full text

Medicine, Dermatology, Pathology +13